| Disease/Trait | glioma |
| LncRNA Target Gene | miR-29c |
| Tissue | glioma tissues, PTBE tissues.Human glioma cell lines (U251, U373, LN229, U118, LN229) |
| Experiment | qPCR, Western blot, Luciferase assay, RIP etc. |
| Function Description | Our data suggest that XIST can amplify the chemoresistance of glioma cell lines to TMZ through directly targetting miR-29c via SP1 and MGMT. XIST/miR-29c may be a potential therapeutic target for glioma treatment.Low XIST expression predicts drug response in PDXs associated with a significant reduction in the breast cancer stem cells population. Kaplan-Meier overall survival curves for 69 patients with glioma classified according to relative XIST expression level.Methylation damage can be reversed by MGMT. In addition, SP1 has been reported to regulate one of the key MMR proteins, MSH6. Recent evidence emphasizes the key regulatory roles of non-coding RNAs (lncRNAs and miRNAs) in tumor biology, including the chemoresistance of cancers.Additionally, the effect of miR-29c mimics or inhibitor on luciferase activity was offset by mutations in XIST. |
| Pubmed ID | 28831025 |
| Year | 2017 |
| Title | LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. |